Pharmaniaga's Regularisation Plan Receives Bursa Approval
Pharmaniaga's Regularisation Plan Receives Bursa Approval
Pharmaniaga Berhad announced that Bursa Malaysia has approved the Group's Regularisation Plan which will see the group looking towards its financial recovery.
Pharmaniaga Berhad宣佈,馬來西亞交易所已批准集團的公司正規化計劃,該計劃將讓集團朝財務恢復的方向努力。
Pharmaniaga Managing Director, Zulkilfli Jafar said, "The approval from Bursa Malaysia paves the way for Pharmaniaga to implement its comprehensive RP, designed to strengthen the Group's financial position, enhance operational efficiencies, and secure long-term growth."
Pharmaniaga董事總經理Zulkilfli Jafar表示:「獲得馬來西亞交易所的批准爲Pharmaniaga開啓了 Comprehensive RP 的大門,旨在加強集團的財務狀況,提升運營效率,並確保長期增長。」
"With this latest development, we are now fully focused on executing the RP and achieving a swift exit from PN17," he said.
「有了這一最新進展,我們現在將全力執行RP並儘快退出PN17,」他說。
The RP outlines strategic initiatives aimed at financial restructuring, business optimisation and strengthening Pharmaniaga's core operations. It represents a proactive approach that will initiate rights issuance to provide the Group's shareholders with an opportunity to reinforce their investments; private placement exercise aimed at drawing potential strategic investors to contribute to the Group's value enhancement and growth in the healthcare sector; and a capital reduction process to adjust the Group's share capital.
RP概述了旨在進行財務重組、業務優化和加強Pharmaniaga核心運營的戰略舉措。這代表了一種積極的方法,將發起權益發行,爲集團股東提供加強投資的機會;定向增發計劃旨在吸引潛在戰略投資者,有助於提升和增長醫療保健板塊的價值;以及進行資本減少流程,調整集團的股本。
Zulkifli further added, "The Group assures its stakeholders, including customers, investors, and business partners, that we remain committed to maintaining the highest standards of service and product quality throughout this period of transformation."
Zulkifli進一步補充說:「集團向利益相關者(包括客戶、投資者和業務夥伴)保證,我們致力於在這一轉型期間保持最高水準的服務和產品質量。」
譯文內容由第三人軟體翻譯。